OBJECTIVE: Efficient antiretroviral therapy (ART) of HIV-1 infection reduces the viral load to undetectable levels and restores the immune system. However, therapy failure appears in a substantial fraction of patients and is mostly associated with the appearance of drug-resistant viruses. It is still not clear when the drug pressure leads to the earliest selection and appearance of drug-resistant HIV-1 populations. In this study, we wanted to determine whether drug-resistant viruses are already selected during viral decline within the first months of ART. DESIGN AND METHODS: Fifteen mostly chronically HIV-1 infected patients were included. None had received ART prior to this study. The selection of three key resistance mutations, L90M (protease), K103N and M184V (reverse transcriptase), were measured by allele-specific real-time PCR allowing us to track minority quasispecies with a discriminative power of 0.01-0.2%. RESULTS: Drug-resistant HIV-1 variants were found in 7/15 patients (46.7%) prior to ART. Rapid selection of drug resistance was detected in six patients (40%) independent of the presence of drug-resistant HIV-1 prior to ART. The risk for the selection of drug resistant viruses was correlated with the time until viral load became undetectable (P = 0.02). Besides the proportional increment of drug-resistant viruses, we observed in two patients a quantitative increase of this virus population while the total viral load decreased. CONCLUSIONS: Drug-resistant viruses can be selected and replicate even in the first weeks of suppressive ART, thus, intensification of ART during the initial treatment period should be considered and further evaluated in clinical studies.
OBJECTIVE: Efficient antiretroviral therapy (ART) of HIV-1 infection reduces the viral load to undetectable levels and restores the immune system. However, therapy failure appears in a substantial fraction of patients and is mostly associated with the appearance of drug-resistant viruses. It is still not clear when the drug pressure leads to the earliest selection and appearance of drug-resistant HIV-1 populations. In this study, we wanted to determine whether drug-resistant viruses are already selected during viral decline within the first months of ART. DESIGN AND METHODS: Fifteen mostly chronically HIV-1 infectedpatients were included. None had received ART prior to this study. The selection of three key resistance mutations, L90M (protease), K103N and M184V (reverse transcriptase), were measured by allele-specific real-time PCR allowing us to track minority quasispecies with a discriminative power of 0.01-0.2%. RESULTS: Drug-resistant HIV-1 variants were found in 7/15 patients (46.7%) prior to ART. Rapid selection of drug resistance was detected in six patients (40%) independent of the presence of drug-resistant HIV-1 prior to ART. The risk for the selection of drug resistant viruses was correlated with the time until viral load became undetectable (P = 0.02). Besides the proportional increment of drug-resistant viruses, we observed in two patients a quantitative increase of this virus population while the total viral load decreased. CONCLUSIONS: Drug-resistant viruses can be selected and replicate even in the first weeks of suppressive ART, thus, intensification of ART during the initial treatment period should be considered and further evaluated in clinical studies.
Authors: Ekachai Jenwitheesuk; Jeremy A Horst; Kasey L Rivas; Wesley C Van Voorhis; Ram Samudrala Journal: Trends Pharmacol Sci Date: 2008-01-10 Impact factor: 14.819
Authors: Valerie F Boltz; Wei Shao; Michael J Bale; Elias K Halvas; Brian Luke; James A McIntyre; Robert T Schooley; Shahin Lockman; Judith S Currier; Fred Sawe; Evelyn Hogg; Michael D Hughes; Mary F Kearney; John M Coffin; John W Mellors Journal: JCI Insight Date: 2019-10-03
Authors: Herbert A Mbunkah; Silvia Bertagnolio; Raph L Hamers; Gillian Hunt; Seth Inzaule; Tobias F Rinke De Wit; Roger Paredes; Neil T Parkin; Michael R Jordan; Karin J Metzner Journal: J Infect Dis Date: 2020-04-27 Impact factor: 5.226
Authors: Karin J Metzner; Christine Leemann; Francesca Di Giallonardo; Christina Grube; Alexandra U Scherrer; Dominique Braun; Herbert Kuster; Rainer Weber; Huldrych F Guenthard Journal: PLoS One Date: 2011-07-06 Impact factor: 3.240
Authors: Joanne D Stekler; Giovanina M Ellis; Jacquelyn Carlsson; Braiden Eilers; Sarah Holte; Janine Maenza; Claire E Stevens; Ann C Collier; Lisa M Frenkel Journal: PLoS One Date: 2011-12-16 Impact factor: 3.240
Authors: Zoe Fox; Andrew Phillips; Cal Cohen; Jacquie Neuhaus; John Baxter; Sean Emery; Bernard Hirschel; Kathy Huppler Hullsiek; Christoph Stephan; Jens Lundgren Journal: AIDS Date: 2008-11-12 Impact factor: 4.177
Authors: Alexandra U Scherrer; Jürg Böni; Sabine Yerly; Thomas Klimkait; Vincent Aubert; Hansjakob Furrer; Alexandra Calmy; Matthias Cavassini; Luigia Elzi; Pietro L Vernazza; Enos Bernasconi; Bruno Ledergerber; Huldrych F Günthard Journal: PLoS One Date: 2012-11-26 Impact factor: 3.240